Dihexa 10mg
For in-vitro laboratory research only. Not for human or animal administration.
Batch #: VPDX10100
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Batch-specific Certificates of Analysis available for all products.
Dihexa 10mg: overview
What the vial contains and what the material is, stated as specifications rather than as outcomes.
Dihexa supplied as a lyophilized powder in a sealed single-use vial containing 10 mg of material. Dihexa: molecular formula C₂₇H₄₄N₄O₅, molecular weight 504.67 g/mol, CAS 1401708-83-5. Released to a specification of >99% purity by HPLC. Soluble in bacteriostatic water. Supplied for in-vitro laboratory research only. Not a drug, food or supplement. Not for human or veterinary use.
Volta does not provide dosing, administration or protocol guidance for any material listed.
Dihexa 10mg specifications
Every field the product record holds. A field with no value is omitted rather than printed as a dash.
- Fill
- 10mg
- Form
- Lyophilized powder
- CAS number
- 1401708-83-5
- Molecular formula
- C₂₇H₄₄N₄O₅
- Molecular weight
- 504.67 g/mol
- Solubility
- Soluble in bacteriostatic water
- Shelf life
- 24 months from date of manufacture
Dihexa analytical verification and batch documentation
What the purity figure on this page is, who measured what, and which of the two a reader is looking at.
Specification. Every batch is released to >99% purity by HPLC. That is a threshold Volta sets, and it is a promise rather than a measurement.
Measurement. No certificate for this compound is published on the site yet. A batch-specific Certificate of Analysis is available on request, and the batch history lists the ones already published. Until one is published for this material, the figure above is the release specification and nothing on this page is a laboratory result.
Checking a certificate. The batch number printed beside the price is derived from the compound code and the vial strength; the lot number on a certificate is transcribed from the document. They are produced independently, so comparing them is a real check. How to read one is set out in the quality and testing methodology page.
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease.
Dihexa came out of work on the angiotensin IV / AT4 receptor system at Washington State University, where the target was a molecule that could cross the blood-brain barrier and promote synapse formation. It does not act as a growth factor itself; the reported mechanism is potentiation of endogenous HGF at c-Met, which places it in a different category from direct receptor agonists. Preclinical reports of potency in synaptogenesis assays are striking, but independent replication remains limited and the compound has no clinical dataset, so it is best treated as exploratory.
- Released to a >99% purity specification by HPLC
- Lyophilized powder, 10mg per vial
- Soluble in bacteriostatic water
- For laboratory research use only
Frequently Bought Together
Dihexa 10mg
10mg
$84 USD
Bundle & Save
$168 USD
Save $8.40 USD
$207 USD
Save $20.70 USD
$251 USD
Save $37.65 USD
$325 USD
Save $65 USD
Click any product above to toggle selection
Related research materials
Dihexa 10mg: what is in the vial
The arithmetic specific to this 10mg vial, and what a milligram of Dihexa costs in each strength the catalogue carries. Concentrations are stated, not recommended.
Vial contents
10 mg
Lyophilised powder, reconstituted by the buyer
Cost of material
$8.40 / mg USD
CA$12 / mg in Canadian dollars
Concentration at each diluent volume
10 mg of dry material reaches these concentrations in the volumes below. A U-100 syringe marking is 0.01 ml by definition, so the last column is a unit conversion at each concentration rather than a quantity to use.
| Diluent added | Concentration | In 0.1 ml | Per U-100 unit |
|---|---|---|---|
| 1 ml | 10 mg/ml | 1 mg | 100 mcg |
| 2 ml | 5 mg/ml | 500 mcg | 50 mcg |
| 3 ml | 3.33 mg/ml | 333.3 mcg | 33.3 mcg |
| 5 ml | 2 mg/ml | 200 mcg | 20 mcg |
For a volume this table does not list, the reconstitution calculator takes any vial size and diluent volume.
Dihexa purity and identity: how the figure is measured
What >99% (HPLC) means, the masses an identity check has to land on, and the entries that make a certificate of analysis checkable rather than decorative.
Stated purity
>99% (HPLC)
Area percent of the main peak by reversed-phase HPLC
Average mass
504.67 g/mol
The figure an identity check has to land on
Identity by mass: the ions to expect
An electrospray source protonates the molecule rather than weighing it neutral, so a spectrum shows a series of charge states rather than the molecular weight itself. These are the m/z values 504.67 g/mol produces, and they are what a mass spectrum on a certificate for Dihexa has to match.
| Ion | Charge | Expected m/z |
|---|---|---|
| [M+H]+ | 1+ | 505.68 |
What a certificate for Dihexa should carry
A purity percentage on its own is not checkable. These are the entries that make one verifiable, and their absence is the most common weakness in a research-peptide certificate.
The chromatogram, not only the number
A stated area percent with no trace behind it cannot be read for the shape of the main peak or for what eluted beside it. The HPLC interpreter walks through what a trace shows.
Net peptide content, separately from gross mass
A lyophilised peptide is a salt, usually of trifluoroacetic or acetic acid, plus residual water. The vial's stated milligrams are gross; net peptide content is the fraction of that mass which is the molecule. The two differ by ten to twenty percent routinely, and only one of them is what the price is per milligram of. The net peptide content calculator converts between them.
The counterion, named
Which salt form the powder is in changes the net content and the pH the powder dissolves at. A certificate that never names it leaves both unknowable.
Water content, by a stated method
Loss on drying and Karl Fischer titration give different numbers, and a water figure with no method attached cannot be compared with anyone else's.
A laboratory and a report identifier
Without both, nothing on the document can be traced back to the laboratory that issued it. The red flag checker lists the rest.
Batch certificates are published as page images in the certificate library. The source PDFs are never served: a certificate is the most forgeable document a supplier publishes, and an editable copy carrying an accredited laboratory's letterhead is worth more to a counterfeiter than to a customer.
Dihexa storage and stability
Handling as the product record states it, followed by the degradation chemistry this particular sequence is and is not exposed to.
Handling
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
A residue-level stability profile needs a primary sequence of standard amino acids. This compound's sequence carries modified or non-standard residues, so no finding is derived for it rather than one being estimated from a partial reading. The storage guide covers the general case.
Dihexa compared with Semax and Adamax
Pharmacological class, half-life, evidence grade, competition status and cost per milligram, side by side.
| Compound | Class | Half-life | Evidence | WADA | Cheapest per mg |
|---|---|---|---|---|---|
| Dihexathis page | Nootropic / Cognitive | Unknown; lipophilic, orally active | FNo Regulatory Activity | Not listed | $8.4010mg vial, out of stock |
| Semax | Nootropic / Neuroprotective | ~3–5 minutes; intranasal extends effective duration | DPreclinical | Not listed | $2.8010mg vial, out of stock |
| Adamax | Cognitive / Nootropic | ~4-6 hours (estimated, extended by adamantane) | DAnimal/Preclinical Only | Not listed | $8.4010mg vial, out of stock |
| Cerebrolysin | Nootropic / Neuroprotective | Not meaningfully defined for a multi-component preparation | CPhase I–II Clinical Trials | Not listed | $0.8260mg vial, out of stock |
| PE-22-28 | Nootropic / Neuroprotective | Improved over spadin in rodent work; not established in humans | DPreclinical Only | Not listed | $5.4010mg vial, out of stock |
Evidence grades and half-lives are as recorded in the compound database, which cites its own sources on each compound page. Per-milligram prices are the cheapest strength each compound is currently listed at, in US dollars, and an out-of-stock note means that figure is not purchasable today. Cross-trial comparisons of efficacy are not comparisons: no head-to-head trial exists for most of these pairs.
Dihexa in Canada
Price in Canadian dollars, where the parcel ships from, and how long it takes.
Price in CAD
CA$120
The figure charged, not a converted estimate
Ships from
British Columbia
A domestic parcel, so no import clearance step
Transit
2 to 5 business days
After 1 to 2 business days of handling
Free standard shipping
Over CA$250
A bar set for this market, not converted from the US one
Dihexa 10mg ships from British Columbia to Canadian addresses, so the parcel never crosses a border. That removes the failure a Canadian buyer of research peptides is usually weighing: an inbound international shipment can be held for import clearance or seized, and a domestic one has no clearance step to be held at.
Shipping is quoted live against the delivery address at checkout rather than estimated here, and both the standard and express tiers show their price and transit window before a payment method is chosen. The figure the page shows is the figure the rail charges: all three settlement rails price shipping through the same functions the quote does.
The Canadian figure above is not a loose conversion. Each product's US dollar base is chosen so that the live conversion lands on the Canadian shelf price set for this market, and the result is pushed up to a whole dollar rather than left carrying cents, so one figure serves the page, the feed and every payment rail. See the shipping policy for carriers and cut-off times, and the legal position on research peptides in Canada for the regulatory picture.
Dihexa Mechanism of Action
Dihexa is a small synthetic molecule derived from angiotensin IV, developed as part of a programme seeking metabolically stable analogues of that peptide with procognitive activity. Angiotensin IV itself is a hexapeptide fragment of the renin-angiotensin system with reported effects on learning and memory, but it is cleared far too rapidly to be useful, and the series Dihexa belongs to exists to solve that.
The mechanism proposed by its developers is that the molecule acts on hepatocyte growth factor and its receptor c-Met, facilitating the dimerisation of HGF that is required for receptor activation. HGF and c-Met signalling is implicated in synaptogenesis, and the reported procognitive and synaptogenic effects of the series are attributed to that pathway rather than to angiotensin receptor activity as such.
That attribution is the part to hold carefully. The published work reports that the procognitive and synaptogenic effects of angiotensin IV-derived peptides depend on activity in this pathway, which is an association established within one research programme. There is no independent structural or biochemical confirmation from another group, and no human data at all.
Origin in the angiotensin IV series
Derived from angiotensin IV, a hexapeptide fragment of the renin-angiotensin system with reported procognitive activity but very rapid clearance.
Metabolic stabilisation
The series was designed specifically to produce analogues that survive long enough to be useful, which is what the evaluation of metabolically stabilised analogues addressed.
Proposed HGF and c-Met involvement
The developers propose that the molecule facilitates dimerisation of hepatocyte growth factor, which is required for activation of its receptor c-Met.
Synaptogenesis
HGF and c-Met signalling is implicated in the formation of synapses, and the reported synaptogenic effects are attributed to this pathway.
Attribution is within one programme
The pathway assignment comes from the originating group's own work and has not been independently confirmed elsewhere.
Dihexa Research Findings
These three studies are the primary literature for this compound in its entirety. All come from the same research programme, and none involves humans.
Procognitive and synaptogenic effects reported for the analogue series
Work reported that the procognitive and synaptogenic effects of angiotensin IV-derived peptides depend on activity in the hepatocyte growth factor pathway, which is the source of the mechanistic attribution made for this compound.
Rodent modelMetabolically stabilised analogues evaluated as antidementia candidates
An evaluation of metabolically stabilised angiotensin IV analogues as procognitive and antidementia agents assessed the series against the stability problem that made the parent peptide unusable.
Rodent modelDevelopment of the small molecule series reviewed
A review traced the development of small molecule angiotensin IV analogues intended for Alzheimer's and Parkinson's disease, setting out the rationale and the state of the programme.
MechanisticNo independent replication exists
The absence is itself a finding worth recording. Searching for this compound returns no work from laboratories unconnected to the originating group, so nothing above has been reproduced under different assumptions or reagents.
ObservationalDihexa Molecular Information
| Class | Small synthetic molecule derived from angiotensin IV. Not a peptide in the usual sense |
| CAS Number | 1401708-83-5 |
| Molecular Weight | 507.6 g/mol |
| Parent Compound | Angiotensin IV, a hexapeptide fragment of the renin-angiotensin system |
| Proposed Target | Hepatocyte growth factor and its receptor c-Met |
| Design Goal | Metabolic stability, which the parent peptide lacks entirely |
| Regulatory Status | Investigational. Not approved in any jurisdiction |
| Development Stage | Preclinical. No human studies |
| Appearance | Solid, typically supplied as a powder |
Three Papers Is the Whole Literature
Most compounds in this catalogue have a literature that can be characterised as thin, narrow or preclinical. Dihexa's is smaller than that. A search returns three directly relevant papers, all from the same research programme at the same institution, spanning roughly 2013 to 2015.
There has been no independent replication in the decade since. That is not a claim that the findings are wrong; it is a statement about how much weight they can carry. A result reproduced by a group with different reagents, assumptions and incentives is a different kind of evidence from a result published three times by the people who discovered it.
Anyone encountering claims about this compound elsewhere should ask which of those three papers the claim traces back to, because in almost every case it will be one of them, restated.
The HGF Attribution Is a Proposal, Not a Demonstration
The mechanistic account offered is that Dihexa facilitates dimerisation of hepatocyte growth factor, enabling activation of c-Met and downstream synaptogenesis. It is a specific and testable proposal, which is more than can be said for several compounds sold alongside it.
It rests on the finding that procognitive and synaptogenic effects of this analogue series depend on activity in that pathway. Dependence established by blocking a pathway is real evidence, but it establishes that the pathway is required rather than that the molecule acts on it directly in the way described.
No independent structural or binding study confirms the proposed interaction with HGF. Until one exists, the mechanism is best described as the developers' hypothesis with supporting functional data from the same laboratory.
What the Absence of Human Data Means Here
There are no human studies of Dihexa at any phase. The compound is often discussed in connection with cognition and neurodegeneration, and those are exactly the areas where animal-to-human translation has the worst historical record of any therapeutic field.
Cognitive enhancement claims are also unusually difficult to evaluate because the endpoints are noisy and the placebo response is large. A rodent behavioural result is a long way from a demonstrated effect in a person.
The compound has no approval in any jurisdiction. Material supplied for research is for in-vitro laboratory use only, and nothing summarised here is guidance for use in humans or animals.
Handling and Analytical Considerations
Dihexa is a small molecule rather than a peptide, so the certificate conventions used elsewhere in this catalogue do not apply. Identity for a compound like this is normally established by nuclear magnetic resonance, with assay by HPLC against a reference standard and residual solvent analysis by gas chromatography.
A certificate reporting only HPLC purity and a mass is a peptide-shaped document applied to something that is not a peptide. With a CAS number available, 1401708-83-5, identity confirmation against a characterised reference is at least possible in principle, which is more than can be said for several compounds on this list.
Dihexa Research FAQ
Dihexa in Summary
Dihexa is a small synthetic molecule from an angiotensin IV analogue series designed for metabolic stability, with a proposed mechanism involving hepatocyte growth factor dimerisation and c-Met activation leading to synaptogenesis.
Its entire primary literature is three papers from one research programme, with no independent replication in roughly a decade and no human studies. The mechanism is a specific and testable proposal rather than a demonstrated one.
Scientific References
Primary literature and public trial registries only. No supplier or retailer pages are cited.
Dihexa has a very small primary literature. A PubMed search returns three directly relevant papers, all from the research group that developed the angiotensin IV analogue series, and there are no independent replications and no human studies of any kind. The references below are that literature in full rather than a selection from a larger body of work. Nothing here has been reproduced by a laboratory unconnected to the originating group.
- 1The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met systemBenoist CC, Kawas LH, Zhu M, et al. · Journal of Pharmacology and Experimental Therapeutics · 2014
- 2Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agentsMcCoy AT, Benoist CC, Wright JW, et al. · Journal of Pharmacology and Experimental Therapeutics · 2013
- 3The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseaseWright JW, Kawas LH, Harding JW · Progress in Neurobiology · 2015
Disclaimer
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are furnished for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.
Dihexa 10mg: frequently asked questions
Answered from the product record and the certificate file. Volta does not answer questions about administration, dosing or protocols.
What is supplied in a 10 mg vial of Dihexa?
A sealed single-use vial containing 10 mg of Dihexa as a lyophilized powder. Soluble in bacteriostatic water. No diluent, syringe or other supply is included.
Is Dihexa supplied for human use?
No. For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Volta does not provide dosing, administration or protocol guidance for any material listed.
What purity is this Dihexa released to?
>99% by HPLC. That figure is a release specification, a threshold Volta sets for every batch, and it is not the same kind of statement as a purity measured by a named laboratory for a named lot.
Is there a certificate of analysis for this Dihexa vial?
A batch-specific Certificate of Analysis is available for this product on request. It is not published on the site yet: the batch history on the quality page lists the certificates already published, and this vial is covered by the release specification until its own is added there.
How is Dihexa identified?
CAS 1401708-83-5, molecular formula C₂₇H₄₄N₄O₅, molecular weight 504.67 g/mol. Those identifiers are what an incoming-goods check compares a certificate against, and they are stated here so the comparison can be made before ordering.
How should Dihexa be stored before reconstitution?
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
Where does this ship from?
British Columbia, Canada. Canadian orders are domestic, so they clear no customs and pay no import duty. International orders ship from the same facility.
Related Research News
Explore Research
Peptide Tools
More from the research catalogue
Every compound below has its own specification, batch number and certificate page, whether or not a vial is in stock today. Supplied for laboratory research use only.
Related research compounds
- DSIP 10mg
- Epithalon 10mg
- Epithalon 50mgrestocking
- FOXO4-DRI 10mgrestocking
- LL-37 5mgrestocking